KTRA — Kintara Therapeutics Share Price
0.000.00%
Last trade - 00:00- $5.91m
- $15.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70880% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.
Directors
- Robert Hoffman PRE (57)
- Scott Praill CFO (55)
- John Liatos SVP (53)
- Dennis Brown CSO (72)
- Steven Rychnovsky VRD (62)
- Laura Johnson IND (57)
- Tamara Seymour IND (63)
- Robert Toth IND (57)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 24th, 2009
- Public Since
- July 12th, 2016
- No. of Shareholders
- 435
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 39,037,899
- Address
- 9920 Pacific Heights Blvd, SAN DIEGO, 92121
- Web
- https://www.kintara.com/
- Phone
- +1 8583504364
- Auditors
- Marcum LLP
Upcoming Events for KTRA
Q3 2024 Kintara Therapeutics Inc Earnings Release
Q4 2024 Kintara Therapeutics Inc Earnings Release
Similar to KTRA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Kintara Therapeutics share price?
As of Today at 19:12 UTC, shares in Kintara Therapeutics are trading at $0.15. This share price information is delayed by 15 minutes.
How has the Kintara Therapeutics share price performed this year?
Shares in Kintara Therapeutics last closed at $0.15 and the price had moved by -96.31% over the past 365 days. In terms of relative price strength the Kintara Therapeutics share price has underperformed the S&P500 Index by -97.02% over the past year.
What are the analyst and broker recommendations for Kintara Therapeutics?
The overall consensus recommendation for Kintara Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kintara Therapeutics dividend yield?
Kintara Therapeutics does not currently pay a dividend.
Does Kintara Therapeutics pay a dividend?
Kintara Therapeutics does not currently pay a dividend.
When does Kintara Therapeutics next pay dividends?
Kintara Therapeutics does not currently pay a dividend.
How do I buy Kintara Therapeutics shares?
To buy shares in Kintara Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kintara Therapeutics?
As of the previous close price of $0.15, shares in Kintara Therapeutics had a market capitalisation of $5.91m.
Where are Kintara Therapeutics shares listed?
Here are the trading details for Kintara Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KTRA
What kind of share is Kintara Therapeutics?
Based on an overall assessment of its quality, value and momentum Kintara Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kintara Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Kintara Therapeutics is $14.00. That is 9153.14% above the last closing price of $0.15.
Analysts covering Kintara Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
What is the trend in the Kintara Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kintara Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -70.72%.
As of the last closing price of $0.15, shares in Kintara Therapeutics were trading -90.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kintara Therapeutics PE Ratio?
The Kintara Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kintara Therapeutics?
Kintara Therapeutics' management team is headed by:
- Robert Hoffman - PRE
- Scott Praill - CFO
- John Liatos - SVP
- Dennis Brown - CSO
- Steven Rychnovsky - VRD
- Laura Johnson - IND
- Tamara Seymour - IND
- Robert Toth - IND